Daniel Martin, MD
Ophthalmology · Atlanta, GANPI 1285651851
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $37,663 of the $55,104 with a category attached, or 68.3%. Ocular Therapeutix, Inc. accounts for 98.2% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $54,231, more than ten times the $355 reported in 2019. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $1574.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$54K
- Regeneron Healthcare Solutions, Inc.$290
- Eyepoint US, Inc.$241
- Johnson & Johnson Surgical Vision, Inc.$208
- Regeneron$134
- Shionogi Inc$45
- plus $95 from 4 others
What the payments were for
- Consulting fees$9,68318%
- Speaking & faculty fees$6,00011%
- Travel & lodging$37,66368%
- Food & beverage$1,7583%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 17 | $54,091 |
| Regeneron Healthcare Solutions, Inc. | 7 | $290 |
| Eyepoint US, Inc. | 2 | $241 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $208 |
| Regeneron | 1 | $134 |
| Shionogi Inc | 2 | $45 |
| Genentech, Inc. | 1 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $25 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,104 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 13 | $88,550 |
| Difluprednate | 12 | $2,655 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $469 |
| Latanoprost | 11 | $165 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Atlanta
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Evan SchoenbergAtlanta$130K
- Robert StultingAtlanta$85K
- David SackelAtlanta$82K
- Atul SharmaAtlanta$77K
- Douglas DayAtlanta$52K
- Jay StallmanAtlanta$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.